Kory James Wentworth is Chief Financial Officer of Entrada Therapeutics, Inc.. Currently has a direct ownership of 73,849 shares of TRDA, which is worth approximately $1.47 Million. The most recent transaction as insider was on Jun 29, 2023, when has been sold 8,790 shares (Common Stock) at a price of $2.1 per share, resulting in proceeds of $18,459. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 73.8K
9.29% 3M change
48.98% 12M change
Total Value Held $1.47 Million

KORY JAMES WENTWORTH Transaction History

Date Transaction Value Shares Traded Shares Held Form
Jun 29 2023
BUY
Exercise of conversion of derivative security
$18,459 $2.1 p/Share
8,790 Added 19.3%
36,747 Common Stock
Jun 21 2023
SELL
Open market or private sale
$262,675 $15.01 p/Share
17,500 Reduced 38.5%
27,957 Common Stock
Jun 21 2023
BUY
Exercise of conversion of derivative security
$36,750 $2.1 p/Share
17,500 Added 27.8%
45,457 Common Stock
Mar 02 2023
SELL
Payment of exercise price or tax liability
$11,658 $11.6 p/Share
1,005 Reduced 2.24%
43,904 Common Stock
Mar 02 2023
SELL
Open market or private sale
$18,954 $10.85 p/Share
1,747 Reduced 3.98%
42,157 Common Stock
Mar 01 2023
BUY
Grant, award, or other acquisition
-
28,400 Added 38.74%
44,909 Common Stock
Dec 08 2022
SELL
Open market or private sale
$86,222 $18.95 p/Share
4,550 Reduced 21.61%
16,509 Common Stock
Dec 08 2022
BUY
Exercise of conversion of derivative security
$9,555 $2.1 p/Share
4,550 Added 17.77%
21,059 Common Stock
Dec 05 2022
SELL
Open market or private sale
$3,610 $18.05 p/Share
200 Reduced 1.2%
16,509 Common Stock
Dec 05 2022
BUY
Exercise of conversion of derivative security
$420 $2.1 p/Share
200 Added 1.18%
16,709 Common Stock
Dec 02 2022
SELL
Open market or private sale
$52,962 $18.2 p/Share
2,910 Reduced 14.99%
16,509 Common Stock
Dec 02 2022
BUY
Exercise of conversion of derivative security
$6,111 $2.1 p/Share
2,910 Added 13.03%
19,419 Common Stock
Nov 16 2022
SELL
Open market or private sale
$3,620 $18.1 p/Share
200 Reduced 1.2%
16,509 Common Stock
Nov 16 2022
BUY
Exercise of conversion of derivative security
$420 $2.1 p/Share
200 Added 1.18%
16,709 Common Stock
Sep 01 2022
BUY
Grant, award, or other acquisition
-
5,503 Added 25.02%
16,489 Common Stock
Aug 25 2022
SELL
Open market or private sale
$21,993 $14.18 p/Share
1,551 Reduced 12.37%
10,986 Common Stock
Aug 24 2022
SELL
Open market or private sale
$43,278 $13.88 p/Share
3,118 Reduced 19.92%
12,537 Common Stock
Aug 24 2022
BUY
Exercise of conversion of derivative security
$2,346 $2.1 p/Share
1,117 Added 6.66%
15,655 Common Stock
Aug 23 2022
SELL
Open market or private sale
$38,079 $13.09 p/Share
2,909 Reduced 16.67%
14,538 Common Stock
Aug 23 2022
BUY
Exercise of conversion of derivative security
$2,946 $2.1 p/Share
1,403 Added 7.44%
17,447 Common Stock
Aug 22 2022
SELL
Open market or private sale
$2,821 $13.0 p/Share
217 Reduced 1.33%
16,044 Common Stock
Aug 22 2022
BUY
Exercise of conversion of derivative security
$246 $2.1 p/Share
117 Added 0.71%
16,261 Common Stock
Aug 19 2022
SELL
Open market or private sale
$111,559 $13.08 p/Share
8,529 Reduced 34.57%
16,144 Common Stock
Aug 19 2022
BUY
Exercise of conversion of derivative security
$9,349 $2.1 p/Share
4,452 Added 15.29%
24,673 Common Stock
Aug 18 2022
SELL
Open market or private sale
$2,600 $13.0 p/Share
200 Reduced 0.98%
20,221 Common Stock
KJW

Kory James Wentworth

Chief Financial Officer
Boston, MA

Track Institutional and Insider Activities on TRDA

Follow Entrada Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells TRDA shares.

Notify only if

Insider Trading

Get notified when an Entrada Therapeutics, Inc. insider buys or sells TRDA shares.

Notify only if

News

Receive news related to Entrada Therapeutics, Inc.

Track Activities on TRDA